Home > Boards > Free Zone > Health and Sciences > Biotech Values

India rejects GILD’s Sovaldi patent, but it probably

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 752
Posts 115,723
Boards Moderated 12
Alias Born 09/05/02
160x600 placeholder
Dow Drops More Than 400 Points on Inflation Worries
Investors around the world retreated from stocks Tuesday, with a selloff in technology companies spreading to other sectors as concerns about inflation spurred a return of volatility in the markets.
Wheat Climbs Amid Final Preparations for WASDE
Caterpillar Announces New Sustainability Goals
Top Company News of the Day
Marc Benioff Says a Ranch May Be What Salesforce's Work Culture Needs
Data on Covid-19 Vaccines for Children Under 12 Expected by Late Fall, Health Officials Say
Canada Asks U.S. Court to Delay Line 5 Pipeline Closure
Bridgewater Founder Ray Dalio Raises Inflation Concerns Over Federal Spending
Dow Drops More Than 500 Points on Inflation Worries
Job Openings Reach Record High Despite Hiring Slowdown -- 2nd Update
Google Plans to Double AI Ethics Research Staff
U.S. Home Prices Surge Higher, Pricing Out Many Buyers
Dow Drops More Than 400 Points As Stock Selloff Extends
Home Depot The Worst Performer in The DJIA So Far Today -- Data Talk
Sampo Oyj Sampo Plc: Disclosure Under Chapter 9 Section 5 Of The Securities Market Act (BlackRock, Inc.)
DoorDash Partners With Rite Aid for Same-Day Delivery
Uber Eats, Peers Given Deadline to Abandon Gig-Worker Model in Spain -- Update
Producer Price Index Growth Expected to Slow -- Data Week Ahead
Stocks Keep Falling, Led by Tech
China Threatens Retaliation Against Ericsson if Sweden Doesn't Drop Huawei 5G Ban
Stocks Open Lower, Led by Tech
Form 8.3 -Willis Towers Watson Plc 11 May 2021
AstraZeneca Hit With Second EU Lawsuit on Vaccine Supplies
AstraZeneca to Talk With Shareholders After Low Support for AGM Resolutions
DewDiligence Member Level  Wednesday, 01/14/15 01:27:33 PM
Re: DewDiligence post# 185958
Post # of 238022 
India rejects GILD’s Sovaldi patent, but it probably doesn’t matter much insofar as GILD previously licensed Sovaldi to various Indian generic-drug companies for a paltry royalty on sales (#msg-105023468):

http://in.reuters.com/article/2015/01/14/us-gilead-india-patent-idINKBN0KN1ZE20150114

The patent decision shows that India still has a long way to go in protecting foreign companies' drug/biotech IP. This is why I was careful to say that the decision in #msg-109867353 did not constitute a trend.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences